Quantitative MRI assessment of treatment response using advanced novel imaging techniques have shown promises for monitoring outcome in patients with symptomatic multiple myeloma (MM), undergoing intensive chemotherapy.
In this work we are investiagting the potential of whole-body mDixon MRI's signal fat fraction early changes as a prognostic imaging biomarker for long-term follow-up of MM patients.
This abstract and the presentation materials are available to members only; a login is required.